Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9501357 | 1.00 | MME (0.48) | MMEHPGDPTGS1PTGS2KMT2A | |
| SCHEMBL9502166 | 0.87 | TAS1R3 (0.50) | HPGDKMT2AMEN1 | |
| SCHEMBL19627057 | 0.86 | PTGS1 (0.49) | MMEHPGDPTGS1PTGS2KMT2A | |
| SCHEMBL10346803 | 0.83 | NPC1 (0.53) | HPGDPTGS2MAPK9ALDH1A1LMNA | |
| SCHEMBL19614361 | 0.80 | RAB9A (0.55) | MMEHPGDKMT2AMEN1MAPK9 | |
| SCHEMBL19614362 | 0.80 | RAB9A (0.55) | MMEHPGDKMT2AMEN1MAPK9 | |
| SCHEMBL13645937 | 0.79 | HPGD (0.67) | HPGDKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL7990464 | 0.78 | MAPK9 (0.54) | MMEHPGDPTGS1PTGS2KMT2A | |
| Acetic Acid SCHEMBL10875129 | 0.78 | PTGS1 (0.51) | MMEHPGDPTGS1PTGS2KMT2A | |
| Acetic Acid SCHEMBL10942103 | 0.78 | PTGS1 (0.51) | MMEHPGDPTGS1PTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920342-B2 | Process for the preparation of Droxidopa | DIVI'S LABORATORIES LIMITED | 2018-03-20 | — | — | US | disclosed |
| US-9920342-B2 | Process for the preparation of Droxidopa | DIVI'S LABORATORIES LIMITED | 2018-03-20 | — | — | US | disclosed |
| US-20170335357-A1 | PROCESS FOR THE PREPARATION OF DROXIDOPA | DIVI'S LABORATORIES LIMITED (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170335357-A1 | PROCESS FOR THE PREPARATION OF DROXIDOPA | DIVI'S LABORATORIES LIMITED (IN) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335357-A1 | PROCESS FOR THE PREPARATION OF DROXIDOPA | DAO, DDO, DNPEP | MME 1073/4885HPGD 781/4885PTGS1 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.